JP Morgan Chase
ANAB icon

JP Morgan Chase’s AnaptysBio ANAB Stock Holding History

JP Morgan Chase’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,500
Closed -$528K – 6321
2021
Q1 		$528K Buy
+24,500
New +$618K ﹤0.01% 4644
2019
Q2 		– Sell
-45,800
Closed -$3.35M – 5753
2019
Q1 		$3.35M Buy
+45,800
New +$3.16M ﹤0.01% 2927

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

JP Morgan Chase's ANAB Position: Q2 2026 in Review

JP Morgan Chase increased its AnaptysBio (ANAB) stake by 589% in Q2 2026, buying an estimated $4.16M and bringing the position to 80,236 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3401.

JP Morgan Chase first reported a position in ANAB in Q1 2017 and has held it in 38 quarters since. The position peaked at $9.02M in Q2 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • JP Morgan Chase held 80,236 shares of AnaptysBio worth $5.29M as of Q2 2026.
  • JP Morgan Chase bought 68,591 AnaptysBio shares in Q2 2026, an estimated $4.16M.
  • AnaptysBio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3401 holding.
  • JP Morgan Chase first reported a position in AnaptysBio in Q1 2017 and has held it in 38 quarters since.
  • JP Morgan Chase's AnaptysBio position peaked at $9.02M in Q2 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.